![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, June 18, 2013 12:29:12 PM
http://files.shareholder.com/downloads/CPRX/2535914370x0x671247/ebace63b-9002-4a51-bdd4-783f9aef298a/CPRX130613.pdf
On June 17, 2013, the Company updated its corporate presentation materials on its website. The updated presentation, which is available on the “Events and Presentations” page on the Company’s website at http://ir.catalystpharma.com/events.cfm, provides the most updated information about the status of the Company’s Phase III clinical trial evaluating Firdapse™ for the treatment of Lambert-Eaton Myasthenic Syndrome.
[chart]img232.imageshack.us/img232/8486/patstackleqr1.jpg
Recent CPRX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 09:00:19 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/07/2024 03:17:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 09:00:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 09:00:21 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/04/2024 02:41:13 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/03/2024 04:22:56 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/31/2024 08:50:35 PM
- Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)] • Edgar (US Regulatory) • 05/31/2024 08:47:26 PM
- Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)] • Edgar (US Regulatory) • 05/31/2024 08:46:49 PM
- Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)] • Edgar (US Regulatory) • 05/31/2024 08:43:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/30/2024 08:43:02 PM
- Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE® • GlobeNewswire Inc. • 05/30/2024 05:41:21 PM
- Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024 • GlobeNewswire Inc. • 05/28/2024 12:03:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2024 09:28:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:54:04 PM
- Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/08/2024 08:16:20 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:06:47 PM
- Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024 • GlobeNewswire Inc. • 05/01/2024 12:00:00 PM
- Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024 • GlobeNewswire Inc. • 04/22/2024 12:00:00 PM
- Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day • GlobeNewswire Inc. • 03/28/2024 12:03:00 PM
- Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium • GlobeNewswire Inc. • 03/27/2024 12:03:00 PM
- Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD) • GlobeNewswire Inc. • 03/13/2024 11:55:00 AM
- Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference • GlobeNewswire Inc. • 03/05/2024 01:03:00 PM
- Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/28/2024 11:03:23 PM
- Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE • GlobeNewswire Inc. • 02/27/2024 01:03:00 PM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM